Homepage4568 • TYO
add
Daiichi Sankyo
Vorige slotkoers
¥ 4.981,00
Dag-range
¥ 4.837,00 - ¥ 5.024,00
Jaar-range
¥ 3.805,00 - ¥ 6.257,00
Beurswaarde
9,48Â bln. JPY
Gem. volume
5,62Â mln.
Koers/winst
40,74
Dividendrendement
1,03%
Primaire beurs
TYO
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(JPY) | sep 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 446,55Â mld. | 18,92% |
Bedrijfskosten | 254,60Â mld. | 10,82% |
Netto inkomsten | 61,29Â mld. | 53,26% |
Netto winstmarge | 13,73 | 28,92% |
Winst per aandeel | — | — |
EBITDA | 110,60Â mld. | 69,06% |
Effectief belastingtarief | 25,60% | — |
Balans
Totale activa
Totale passiva
(JPY) | sep 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 707,67Â mld. | 19,79% |
Totale activa | 3,30Â bln. | 24,46% |
Totale passiva | 1,67Â bln. | 58,69% |
Totaal aandelenvermogen | 1,62 bln. | — |
Uitstaande aandelen | 1,90 mld. | — |
Koers-boekwaardeverhouding | 5,82 | — |
Rendement op activa | 6,97% | — |
Rendement op kapitaal | 13,24% | — |
Kasstroom
Nettomutatie in liquide middelen
(JPY) | sep 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 61,29Â mld. | 53,26% |
Operationele kasstroom | 33,49Â mld. | 284,55% |
Kasstroom uit beleggingen | -10,87Â mld. | -108,72% |
Kasstroom uit financiering | -78,62Â mld. | -75,67% |
Nettomutatie in liquide middelen | -97,59Â mld. | -237,26% |
Vrije kasstroom | 53,27Â mld. | -46,31% |
Over
Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.
Daiichi Sankyo, Inc. began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo Company, Limited, and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development, is headquartered in Basking Ridge, New Jersey.
Daiichi Sankyo Europe, GmbH, the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries.
Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations and of the International Federation of Pharmaceutical Manufacturers and Associations. Wikipedia
CEO
Opgericht
28 sep 2005
Hoofdvestiging
Website
Werknemers
18.726